Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Visx/Laser Vision Centers

This article was originally published in The Gray Sheet

Executive Summary

Visx/Laser Vision Centers: Sign purchasing contract under which LVC agrees to buy 20 Visx Star ophthalmic excimer laser systems "subject to Visx' production schedule," LVC states. The deal, which includes an option to purchase up to 20 additional units over the next year, would be worth "over $20 mil." if fully exercised, according to LVC. The Visx laser is approved for phototherapeutic keratectomy; on Oct. 20 the device received a conditional approval recommendation from FDA's Ophthalmic Devices Advisory Panel for use in photorefractive keratectomy ("The Gray Sheet" Oct. 23, I&W-21)...

You may also be interested in...



Brexit: New Rules Will Hit Parallel Trade From UK to EU

Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway 

Health And Wellness Trademark Review 24 November, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Post-Brexit MHRA Will Embrace Medtech ‘Innovation Pull’ In The UK

The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel